Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arthritis, Rheumatoid | 31 | 2024 | 3763 | 1.880 |
Why?
|
Antirheumatic Agents | 20 | 2024 | 1372 | 1.660 |
Why?
|
Lupus Erythematosus, Systemic | 25 | 2024 | 2155 | 1.650 |
Why?
|
Lupus Nephritis | 6 | 2024 | 316 | 0.570 |
Why?
|
Hydroxychloroquine | 5 | 2015 | 426 | 0.530 |
Why?
|
Fever of Unknown Origin | 1 | 2016 | 94 | 0.530 |
Why?
|
Rheumatic Diseases | 7 | 2021 | 649 | 0.500 |
Why?
|
Rheumatology | 5 | 2021 | 615 | 0.440 |
Why?
|
Leiomyosarcoma | 1 | 2016 | 422 | 0.410 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2012 | 445 | 0.380 |
Why?
|
PPAR gamma | 1 | 2013 | 484 | 0.340 |
Why?
|
Thiazolidinediones | 1 | 2013 | 461 | 0.340 |
Why?
|
Complement C3 | 3 | 2020 | 435 | 0.330 |
Why?
|
Complement Activation | 3 | 2020 | 445 | 0.320 |
Why?
|
Immunoconjugates | 4 | 2008 | 954 | 0.300 |
Why?
|
Glucocorticoids | 3 | 2016 | 2161 | 0.300 |
Why?
|
Uterine Neoplasms | 1 | 2016 | 1420 | 0.290 |
Why?
|
Polyethylene Glycols | 2 | 2012 | 1189 | 0.290 |
Why?
|
Chemokine CXCL13 | 2 | 2024 | 59 | 0.270 |
Why?
|
Complement C4 | 3 | 2020 | 217 | 0.250 |
Why?
|
Antibodies, Antinuclear | 7 | 2021 | 343 | 0.220 |
Why?
|
Insulin Resistance | 3 | 2014 | 3963 | 0.220 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2015 | 61 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2024 | 286 | 0.220 |
Why?
|
Synovial Fluid | 6 | 2023 | 393 | 0.220 |
Why?
|
Arthritis, Infectious | 2 | 2002 | 347 | 0.220 |
Why?
|
Lipids | 1 | 2014 | 3341 | 0.210 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2011 | 4352 | 0.210 |
Why?
|
Coronary Circulation | 3 | 2024 | 1569 | 0.210 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2024 | 220 | 0.200 |
Why?
|
Arteritis | 1 | 2024 | 158 | 0.190 |
Why?
|
Lyme Disease | 2 | 2002 | 631 | 0.190 |
Why?
|
Complement C4b | 2 | 2019 | 126 | 0.190 |
Why?
|
Drug Substitution | 1 | 2024 | 290 | 0.190 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9177 | 0.180 |
Why?
|
Disease Progression | 5 | 2019 | 13506 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2024 | 4369 | 0.180 |
Why?
|
Europe | 4 | 2019 | 3422 | 0.180 |
Why?
|
Arthritis, Psoriatic | 1 | 2023 | 219 | 0.180 |
Why?
|
Societies, Medical | 4 | 2019 | 3905 | 0.180 |
Why?
|
Interferon Type I | 1 | 2024 | 562 | 0.180 |
Why?
|
Inflammation | 6 | 2024 | 10773 | 0.170 |
Why?
|
Myocardial Perfusion Imaging | 2 | 2024 | 575 | 0.170 |
Why?
|
Microcirculation | 1 | 2024 | 1273 | 0.160 |
Why?
|
Lymphoma, B-Cell | 1 | 2005 | 940 | 0.160 |
Why?
|
Macrophage Activation | 1 | 2022 | 553 | 0.160 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 1136 | 0.150 |
Why?
|
HLA-DR Antigens | 3 | 2018 | 602 | 0.150 |
Why?
|
Middle Aged | 44 | 2024 | 220895 | 0.140 |
Why?
|
Humans | 74 | 2024 | 761504 | 0.140 |
Why?
|
Spin Labels | 1 | 2019 | 337 | 0.140 |
Why?
|
Pain Measurement | 2 | 2019 | 3550 | 0.140 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2024 | 974 | 0.130 |
Why?
|
Medication Adherence | 2 | 2018 | 2176 | 0.130 |
Why?
|
Bacteria, Anaerobic | 1 | 1996 | 70 | 0.130 |
Why?
|
Anorexia | 1 | 2016 | 154 | 0.130 |
Why?
|
Severity of Illness Index | 6 | 2020 | 15842 | 0.130 |
Why?
|
B-Lymphocytes | 4 | 2020 | 4758 | 0.130 |
Why?
|
Bursitis | 1 | 1996 | 80 | 0.130 |
Why?
|
Liver Function Tests | 1 | 2016 | 523 | 0.120 |
Why?
|
Female | 49 | 2024 | 392644 | 0.120 |
Why?
|
Clinical Trials as Topic | 2 | 2008 | 8002 | 0.120 |
Why?
|
Biological Products | 1 | 2024 | 914 | 0.120 |
Why?
|
Interferon-alpha | 2 | 2017 | 921 | 0.120 |
Why?
|
Peptides, Cyclic | 2 | 2007 | 392 | 0.120 |
Why?
|
Cyclopropanes | 1 | 2015 | 432 | 0.110 |
Why?
|
Methotrexate | 5 | 2012 | 1719 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2019 | 5112 | 0.110 |
Why?
|
Male | 44 | 2024 | 360804 | 0.110 |
Why?
|
Coronary Vessels | 2 | 2024 | 3096 | 0.110 |
Why?
|
Coronary Artery Disease | 3 | 2024 | 6403 | 0.110 |
Why?
|
Sensitivity and Specificity | 8 | 2021 | 14666 | 0.110 |
Why?
|
Autoimmune Diseases | 1 | 2005 | 2244 | 0.110 |
Why?
|
Treatment Outcome | 16 | 2024 | 64680 | 0.110 |
Why?
|
Biopsy | 4 | 2019 | 6766 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4580 | 0.100 |
Why?
|
Cough | 1 | 2016 | 594 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2019 | 815 | 0.100 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2005 | 694 | 0.100 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2019 | 782 | 0.100 |
Why?
|
Probenecid | 1 | 1992 | 73 | 0.100 |
Why?
|
Erythromycin | 1 | 1992 | 115 | 0.100 |
Why?
|
Receptors, Complement | 1 | 2012 | 253 | 0.100 |
Why?
|
Panniculitis | 1 | 2012 | 45 | 0.100 |
Why?
|
Erythrocytes | 3 | 2020 | 2413 | 0.100 |
Why?
|
Ferritins | 1 | 2015 | 598 | 0.100 |
Why?
|
Adult | 34 | 2024 | 221177 | 0.100 |
Why?
|
Cross-Over Studies | 2 | 2015 | 2078 | 0.100 |
Why?
|
Rheumatoid Factor | 4 | 2019 | 185 | 0.100 |
Why?
|
Urban Health Services | 1 | 2012 | 177 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2113 | 0.100 |
Why?
|
Lupus Vasculitis, Central Nervous System | 1 | 2011 | 32 | 0.100 |
Why?
|
Aged | 24 | 2024 | 169289 | 0.090 |
Why?
|
Biological Therapy | 1 | 2012 | 141 | 0.090 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2015 | 269 | 0.090 |
Why?
|
Joints | 1 | 2012 | 322 | 0.090 |
Why?
|
Hand | 1 | 1996 | 902 | 0.090 |
Why?
|
Amoxicillin | 1 | 1992 | 180 | 0.090 |
Why?
|
Models, Econometric | 2 | 2008 | 216 | 0.090 |
Why?
|
Blood Platelets | 2 | 2012 | 2479 | 0.090 |
Why?
|
Diagnosis, Differential | 4 | 2019 | 12974 | 0.090 |
Why?
|
Phospholipases A2, Secretory | 1 | 2010 | 30 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1802 | 0.090 |
Why?
|
Medically Underserved Area | 1 | 2012 | 254 | 0.090 |
Why?
|
Double-Blind Method | 5 | 2015 | 12341 | 0.090 |
Why?
|
Cholecalciferol | 1 | 2015 | 553 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12148 | 0.090 |
Why?
|
Doxycycline | 1 | 1992 | 344 | 0.090 |
Why?
|
Remission Induction | 2 | 2012 | 2396 | 0.090 |
Why?
|
Lichenoid Eruptions | 1 | 2009 | 13 | 0.080 |
Why?
|
Antigens | 1 | 2015 | 1443 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2015 | 1342 | 0.080 |
Why?
|
Arthritis | 2 | 2010 | 680 | 0.080 |
Why?
|
Endocrine System Diseases | 1 | 2011 | 249 | 0.080 |
Why?
|
Dermatomyositis | 1 | 2012 | 258 | 0.080 |
Why?
|
Autoantibodies | 3 | 2019 | 2116 | 0.080 |
Why?
|
Consensus | 1 | 2018 | 3123 | 0.080 |
Why?
|
Disability Evaluation | 3 | 2011 | 1835 | 0.080 |
Why?
|
Listeriosis | 1 | 1990 | 149 | 0.080 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2024 | 323 | 0.080 |
Why?
|
Antigen-Antibody Complex | 1 | 2010 | 510 | 0.080 |
Why?
|
Synovial Membrane | 3 | 2022 | 532 | 0.080 |
Why?
|
Cell-Derived Microparticles | 1 | 2010 | 161 | 0.080 |
Why?
|
Bacterial Infections | 1 | 1996 | 1390 | 0.070 |
Why?
|
Hazardous Waste | 1 | 2007 | 24 | 0.070 |
Why?
|
C-Reactive Protein | 2 | 2024 | 3826 | 0.070 |
Why?
|
Pilot Projects | 4 | 2018 | 8631 | 0.070 |
Why?
|
Kidney | 2 | 2019 | 7048 | 0.070 |
Why?
|
Knee Prosthesis | 1 | 1990 | 395 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2019 | 2223 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 3 | 2015 | 357 | 0.070 |
Why?
|
HLA-DR3 Antigen | 1 | 2005 | 24 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2011 | 970 | 0.060 |
Why?
|
Morbidity | 1 | 2011 | 1750 | 0.060 |
Why?
|
Organogold Compounds | 1 | 2005 | 4 | 0.060 |
Why?
|
Psoriasis | 2 | 2011 | 950 | 0.060 |
Why?
|
Insurance Claim Review | 1 | 2010 | 741 | 0.060 |
Why?
|
Interleukin-2 | 1 | 1992 | 1889 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2020 | 5869 | 0.060 |
Why?
|
Young Adult | 10 | 2024 | 59243 | 0.060 |
Why?
|
Glutathione Transferase | 1 | 2007 | 565 | 0.060 |
Why?
|
Diabetes Mellitus | 3 | 2011 | 5840 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2009 | 1702 | 0.060 |
Why?
|
Receptors, Interleukin-6 | 1 | 2005 | 226 | 0.060 |
Why?
|
Genetic Markers | 1 | 2010 | 2601 | 0.060 |
Why?
|
Liver | 2 | 2016 | 7529 | 0.060 |
Why?
|
Epitopes | 2 | 2007 | 2503 | 0.060 |
Why?
|
United States | 7 | 2021 | 72334 | 0.050 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2005 | 457 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9280 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2011 | 1200 | 0.050 |
Why?
|
Skin Diseases | 1 | 2011 | 1094 | 0.050 |
Why?
|
Work Capacity Evaluation | 1 | 2002 | 44 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2015 | 4936 | 0.050 |
Why?
|
Case-Control Studies | 5 | 2021 | 22176 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 15500 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 348 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 2273 | 0.050 |
Why?
|
Cytokines | 2 | 2022 | 7396 | 0.050 |
Why?
|
Collagen | 1 | 2010 | 2638 | 0.050 |
Why?
|
Pain | 1 | 2016 | 5073 | 0.050 |
Why?
|
Gene Expression Regulation | 2 | 2019 | 11903 | 0.050 |
Why?
|
Lung Diseases | 1 | 2011 | 1909 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2015 | 2947 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2014 | 3600 | 0.050 |
Why?
|
Positron-Emission Tomography | 3 | 2024 | 6485 | 0.050 |
Why?
|
Granzymes | 1 | 2022 | 277 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2011 | 2091 | 0.040 |
Why?
|
North America | 2 | 2018 | 1276 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2010 | 1809 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9420 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20570 | 0.040 |
Why?
|
Borrelia burgdorferi | 1 | 2002 | 183 | 0.040 |
Why?
|
Managed Care Programs | 1 | 2005 | 940 | 0.040 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2019 | 40 | 0.040 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2019 | 71 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 2449 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2024 | 4174 | 0.040 |
Why?
|
Troponin T | 1 | 2024 | 780 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2008 | 1589 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2471 | 0.040 |
Why?
|
Epigenomics | 1 | 2024 | 943 | 0.040 |
Why?
|
Interleukin-1beta | 1 | 2024 | 999 | 0.040 |
Why?
|
Adolescent | 7 | 2024 | 88319 | 0.040 |
Why?
|
Sjogren's Syndrome | 1 | 2019 | 237 | 0.040 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12059 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 4021 | 0.040 |
Why?
|
Macrophage-Activating Factors | 1 | 2017 | 21 | 0.040 |
Why?
|
Fibromyalgia | 1 | 2002 | 405 | 0.040 |
Why?
|
Adrenalectomy | 1 | 2019 | 346 | 0.040 |
Why?
|
Receptors, CXCR5 | 1 | 2017 | 88 | 0.030 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3358 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2019 | 522 | 0.030 |
Why?
|
Urban Population | 1 | 2005 | 2036 | 0.030 |
Why?
|
Quality of Life | 5 | 2012 | 13367 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2021 | 973 | 0.030 |
Why?
|
Research Design | 1 | 2012 | 6180 | 0.030 |
Why?
|
Lymphopenia | 1 | 2018 | 281 | 0.030 |
Why?
|
Peptostreptococcus | 1 | 1996 | 29 | 0.030 |
Why?
|
Veillonella | 1 | 1996 | 21 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 191 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2015 | 10766 | 0.030 |
Why?
|
Polymyalgia Rheumatica | 1 | 1996 | 52 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4243 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2023 | 1784 | 0.030 |
Why?
|
Complement System Proteins | 1 | 2019 | 736 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 3 | 2007 | 17904 | 0.030 |
Why?
|
Delphi Technique | 1 | 2019 | 846 | 0.030 |
Why?
|
Interferons | 1 | 2019 | 706 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2024 | 1886 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 4876 | 0.030 |
Why?
|
Qualitative Research | 2 | 2018 | 3023 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5440 | 0.030 |
Why?
|
Wrist | 1 | 1996 | 227 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2018 | 1351 | 0.030 |
Why?
|
Health Status | 1 | 2008 | 4077 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2022 | 4575 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6346 | 0.030 |
Why?
|
Cystectomy | 1 | 2019 | 634 | 0.030 |
Why?
|
Cohort Studies | 5 | 2021 | 41487 | 0.030 |
Why?
|
Databases, Factual | 1 | 2010 | 7967 | 0.030 |
Why?
|
Myeloid Cells | 1 | 2019 | 823 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2019 | 1870 | 0.030 |
Why?
|
Population Surveillance | 1 | 2005 | 2598 | 0.030 |
Why?
|
Self Report | 2 | 2015 | 3724 | 0.030 |
Why?
|
Osteoarthritis | 1 | 2002 | 1063 | 0.030 |
Why?
|
Follow-Up Studies | 5 | 2015 | 39106 | 0.030 |
Why?
|
Receptors, Chemokine | 1 | 2017 | 652 | 0.030 |
Why?
|
Azathioprine | 1 | 2015 | 354 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2024 | 11528 | 0.030 |
Why?
|
Th1 Cells | 1 | 2018 | 1036 | 0.030 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1996 | 343 | 0.030 |
Why?
|
International Cooperation | 1 | 2019 | 1422 | 0.030 |
Why?
|
Carpal Tunnel Syndrome | 1 | 1996 | 303 | 0.030 |
Why?
|
Iron Overload | 1 | 2015 | 239 | 0.030 |
Why?
|
Arthritis, Reactive | 1 | 1992 | 20 | 0.030 |
Why?
|
Pamphlets | 1 | 2012 | 71 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2010 | 10194 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2015 | 749 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2009 | 10209 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2019 | 2707 | 0.020 |
Why?
|
Borrelia burgdorferi Group | 1 | 1992 | 97 | 0.020 |
Why?
|
Interleukins | 1 | 2017 | 782 | 0.020 |
Why?
|
Erythema Chronicum Migrans | 1 | 1992 | 48 | 0.020 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 26125 | 0.020 |
Why?
|
Vimentin | 1 | 2012 | 255 | 0.020 |
Why?
|
Brain | 1 | 2019 | 27112 | 0.020 |
Why?
|
Retrospective Studies | 6 | 2021 | 80636 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2018 | 1359 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2007 | 4486 | 0.020 |
Why?
|
Pain Threshold | 1 | 2015 | 604 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2022 | 18965 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2612 | 0.020 |
Why?
|
Self-Help Groups | 1 | 2012 | 192 | 0.020 |
Why?
|
Acute Disease | 1 | 2022 | 7237 | 0.020 |
Why?
|
Leukocytes | 1 | 2019 | 2026 | 0.020 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 206 | 0.020 |
Why?
|
Prostatectomy | 1 | 2019 | 1824 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2018 | 1181 | 0.020 |
Why?
|
Azithromycin | 1 | 1992 | 199 | 0.020 |
Why?
|
Alleles | 3 | 2007 | 6863 | 0.020 |
Why?
|
Receptors, Collagen | 1 | 2010 | 25 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 1992 | 712 | 0.020 |
Why?
|
Smoking | 1 | 2007 | 9053 | 0.020 |
Why?
|
Sensation | 1 | 1992 | 337 | 0.020 |
Why?
|
DNA | 2 | 2015 | 7212 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2015 | 2927 | 0.020 |
Why?
|
Drug Costs | 2 | 2008 | 1183 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2019 | 58976 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 12947 | 0.020 |
Why?
|
Social Isolation | 1 | 2012 | 364 | 0.020 |
Why?
|
Logistic Models | 2 | 2015 | 13255 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 14031 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.020 |
Why?
|
Crohn Disease | 1 | 2022 | 2279 | 0.020 |
Why?
|
Regression Analysis | 2 | 2010 | 6343 | 0.020 |
Why?
|
Telephone | 1 | 2012 | 627 | 0.020 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2010 | 284 | 0.020 |
Why?
|
Renal Insufficiency | 1 | 2015 | 809 | 0.020 |
Why?
|
Lichen Planus | 1 | 2009 | 70 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15266 | 0.020 |
Why?
|
Anti-Bacterial Agents | 2 | 2002 | 7407 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4920 | 0.020 |
Why?
|
Syndrome | 1 | 2015 | 3267 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4244 | 0.020 |
Why?
|
Dermatologic Agents | 1 | 2012 | 313 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1242 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4853 | 0.020 |
Why?
|
Community Health Services | 1 | 2012 | 656 | 0.020 |
Why?
|
Comorbidity | 2 | 2013 | 10508 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 1996 | 1880 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2019 | 3673 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3518 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 1992 | 1527 | 0.020 |
Why?
|
Risk Factors | 5 | 2022 | 74206 | 0.020 |
Why?
|
Boston | 2 | 2012 | 9326 | 0.020 |
Why?
|
Peer Group | 1 | 2012 | 692 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9318 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 29625 | 0.020 |
Why?
|
Focus Groups | 1 | 2012 | 1413 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2008 | 6310 | 0.020 |
Why?
|
Platelet Activation | 1 | 2010 | 645 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1897 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2009 | 335 | 0.020 |
Why?
|
Interleukin-1 | 1 | 2010 | 1248 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 1992 | 1469 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2017 | 2986 | 0.020 |
Why?
|
Canada | 1 | 2011 | 2122 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2005 | 15936 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2759 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2008 | 5492 | 0.020 |
Why?
|
Infusions, Parenteral | 1 | 2005 | 397 | 0.020 |
Why?
|
Patient Preference | 1 | 2012 | 924 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3249 | 0.020 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2005 | 64 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5203 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2015 | 2898 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1547 | 0.010 |
Why?
|
Medical Records | 1 | 2010 | 1408 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 857 | 0.010 |
Why?
|
Drug Utilization Review | 1 | 2005 | 248 | 0.010 |
Why?
|
Body Mass Index | 2 | 2012 | 12953 | 0.010 |
Why?
|
False Negative Reactions | 1 | 2005 | 573 | 0.010 |
Why?
|
Time Factors | 3 | 2014 | 39967 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 54425 | 0.010 |
Why?
|
Hematologic Neoplasms | 1 | 2015 | 1896 | 0.010 |
Why?
|
Incidence | 2 | 2011 | 21353 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10445 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2319 | 0.010 |
Why?
|
Health Services Research | 1 | 2010 | 1812 | 0.010 |
Why?
|
Dietary Supplements | 1 | 2015 | 3415 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2010 | 1726 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2011 | 1797 | 0.010 |
Why?
|
Vitamin D | 1 | 2015 | 3303 | 0.010 |
Why?
|
Nervous System Diseases | 1 | 1992 | 1666 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2007 | 12463 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2008 | 1722 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2010 | 6216 | 0.010 |
Why?
|
Emotions | 1 | 2012 | 2739 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5871 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1992 | 4544 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 2005 | 1998 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12725 | 0.010 |
Why?
|
Occupations | 1 | 2002 | 515 | 0.010 |
Why?
|
Haplotypes | 1 | 2005 | 2713 | 0.010 |
Why?
|
Fibroblasts | 1 | 2010 | 4141 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9610 | 0.010 |
Why?
|
Insurance, Health | 1 | 2011 | 2498 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2010 | 20098 | 0.010 |
Why?
|
Mental Health | 1 | 2012 | 3250 | 0.010 |
Why?
|
Gene Frequency | 1 | 2005 | 3606 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2012 | 4016 | 0.010 |
Why?
|
Gene Expression | 1 | 2010 | 7581 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2010 | 9539 | 0.010 |
Why?
|
Sex Factors | 1 | 2011 | 10552 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18395 | 0.010 |
Why?
|
Registries | 1 | 2012 | 8224 | 0.010 |
Why?
|
Blood Glucose | 1 | 2010 | 6391 | 0.010 |
Why?
|
Insulin | 1 | 2010 | 6596 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2011 | 4234 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2012 | 14605 | 0.010 |
Why?
|
Genetic Variation | 1 | 2010 | 6567 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3242 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14414 | 0.010 |
Why?
|
Phenotype | 1 | 1992 | 16591 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15732 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2002 | 6228 | 0.010 |
Why?
|
Pregnancy | 1 | 2015 | 29874 | 0.010 |
Why?
|
Mice | 2 | 2010 | 81525 | 0.010 |
Why?
|
Survival Analysis | 1 | 2005 | 10090 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 12990 | 0.010 |
Why?
|
Psychometrics | 1 | 2002 | 3065 | 0.010 |
Why?
|
Massachusetts | 1 | 2005 | 8830 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 22169 | 0.010 |
Why?
|
Hypertension | 1 | 2011 | 8540 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18252 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 42230 | 0.000 |
Why?
|
Animals | 2 | 2010 | 168459 | 0.000 |
Why?
|
Neoplasms | 1 | 1992 | 22170 | 0.000 |
Why?
|
Child | 1 | 2011 | 80153 | 0.000 |
Why?
|